Slide Presentations: Wednesday, November 3, 2010 |

Influence of Severe Comorbidities on the Effects of Dopamine and Norepinephrine for the Treatment of Shock FREE TO VIEW

Daniel De Backer, MD; Patrick Biston, MD; Jacques Devriendt, MD; Christian Madl, MD; Didier Chochrad, MD; Cesar Aldecoa, MD; Jean-Louis Vincent, MD
Author and Funding Information

Erasme University Hospital, Brussels, Belgium

Chest. 2010;138(4_MeetingAbstracts):896A. doi:10.1378/chest.10808
Text Size: A A A
Published online


PURPOSE: We recently demonstrated that, compared to norepinephrine, dopamine was associated with a non significant increase in 28 day mortality (odds ratio 1.17 [0.97-1.42]) and also more arrhythmias (De Backer et al NEJM 362:779-789;2010). However, the study had very few exclusion criteria , so that some comorbidities. may have diluted the impact of the vasoactive agents. We conducted a per-protocol analysis limited to patients without major comorbidities.

METHODS: In a prospective, randomized study (NCT00314704), 858 patients received dopamine and 821 norepinephrine, according to a protocol described in detail elsewhere (De Backer et al NEJM 362:779-789;2010). In a univariate analysis, we first determined which factors were associated with an increased risk of death at day-28. After discarding patients with these severe comorbidities, we evaluated the odds ratios of 28-day survival and incidence of arrhythmias. Chi square and T-test were used to compare the effects of both agents and a p value <0.05 was considered as significant.

RESULTS: Advanced cancer, liver cirrhosis with Child Pugh score 3 and prior cardiac arrest were associated with increased risk of death. After discarding these patients, 1303 patients were kept for analysis, 662 in dopamine and 641 in norepinephrine group. The odds ratio for 28-day mortality associated with dopamine were 1.16 [0.93-1.44], p=0.21. The incidence of arrhythmias was 25.9% in dopamine and 22.5% in norepinephrine group (p<0.001).

CONCLUSION: Inclusion of patients with severe comorbidities did not influence the results of the trial. Dopamine remains associated with a non significant increased risk of death at day 28 and with a significant increased incidence of cardiac arrhythmias.

CLINICAL IMPLICATIONS: Norepinephrine should be preferred over dopamine as the first agent for the treatment of shock.

DISCLOSURE: Daniel De Backer, No Financial Disclosure Information; No Product/Research Disclosure Information

08:00 AM - 09:15 AM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543